Actively Recruiting
A Phase 2, Randomized, Double-blind, Placebo-controlled Trial to Investigate the Efficacy and Safety of 2 Doses of Vipoglanstat in Patients With Moderate to Severe Endometriosis-related Pain - the NOVA Trial
Led by Gesynta Pharma AB · Updated on 2026-04-17
190
Participants Needed
41
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the effects of vipoglanstat on non-menstrual pelvic pain NMPP related to endometriosis in women aged 18 to 44 years. This Phase 2 trial aims to assess how well vipoglanstat works and its safety in treating moderate to severe pain caused by endometriosis. The study is sponsored by Gesynta Pharma AB and is designed as a randomized, double-blind, placebo-controlled trial.
CONDITIONS
Brief Title
A Phase 2 Trial to Investigate Efficacy and Safety of Vipoglanstat in Women With Endometriosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Premenopausal females 18 to under 45 years old at Visit 1
- Confirmed diagnosis of endometriosis within the last 10 years by surgery or imaging
- History of non-menstrual pelvic pain significantly affecting daily life
- Reports moderate to very severe pain during non-menstrual days in the month before Visit 2
You will not qualify if you...
- Chronic pelvic pain not primarily caused by endometriosis (such as chronic infection, interstitial cystitis, nerve problems, non-endometriosis pelvic adhesions, persistent ovarian cysts, posttubal ligation, hydrosalpinx, or vaginismus)
- More than two prior surgical procedures for endometriosis
Research Team
C
CMO VP Clinical Development
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here